Summary Cellular insensitivity to vinca alkaloids is suggested to be primarily due to drug efflux by P-glycoprotein (P-gp). The anti-epileptic phenytoin (DPH), which does not bind to P-gp, can selectively enhance vincristine (VCR) cytotoxicity in wild-type (WT) or multidrug-resistant (MDR) cells. We now demonstrate that the protein phosphatase inhibitor okadaic acid (OKA) can mimic the effect of DPH by selectively enhancing cytotoxicity of vinblastine (VBL), but not taxol and doxorubicin, in human leukaemia HL-60 cells. Both DPH and OKA potentiate the anti-mitotic effects of VBL by enhanced damage to the mitotic spindle, resulting in prolonged growth arrest. Also, unlike VBL alone, in human leukaemia or non-small-cell lung carcinoma cells treated with VBL plus DPH, recovery from damage to the mitotic spindle is compromised in drug-free medium and cell death by apoptosis in interphase ensues. Since protein phosphatases are involved with the regulation of metaphase to anaphase transit of cells during the mitotic cycle, enhanced VBL cytotoxicity in the presence of DPH or OKA may involve effects during metaphase on the mitotic spindle tubulin leading to growth arrest and apoptosis in interphase. These novel results suggest that DPH or OKA could be powerful tools to study cellular effects of vinca alkaloids and possibly for the development of novel therapeutic strategies.
Tumour cell resistance to drugs that differ both in structure and/or mechanism of action is suggested to be primarily due to efflux of drug against a concentration gradient by the membrane protein, P-glycoprotein (Endicott and Ling, 1989; Gottesman and Pastan, 1993) . Cellular insensitivity to the clinically important anti-tumor vinca alkaloids vincristine (VCR) or vinblastine (VBL) is attributed to overexpression of P-glycoprotein (P-gp), and interfering with P-gp activity is a strategy widely adopted for enhancing drug cytotoxicity (Georges et al., 1990) . We have previously reported that the anti-epileptic phenytoin (DPH), which can affect microtubule polymerisation selectively, enhances the cytotoxic effects of VCR in wild-type (WT) or multidrug-resistant (MDR) cells (Rall and Schleiffer, 1990; Ganapathi et al., 1993) . A notable characteristic of DPH is its ability to enhance VCR cytotoxicity without binding to P-gp or enhancing drug accumulation (Ganapathi et al., 1993) . Also while the effects of DPH were selective for VCR, concentrations of DPH that enhanced cytotoxicity were markedly lower than those reported to inhibit tubulin polymerisation (MacKinney et al., 1978 (MacKinney et al., , 1980 Ganapathi et al., 1993) .
The treatment of cells with the protein phosphatase inhibitor okadaic acid (OKA) can produce an anti-mitotic effect (Yamashita et al., 1990; Vandre and Wills, 1992) . Further, protein phosphatases have also been suggested to be involved in mitotic exit as well as cytoskeletal integrity (Eriksson et al., 1992; Fernande et al., 1992; Gurland and Gundersen, 1993) . Since the anti-mitotic effect of OKA or DPH compared with that induced by VBL may involve distinctly different mechanisms, we have investigated the cellular effects induced by VBL in the presence of non-cytotoxic concentrations of DPH or OKA in human tumour cells.
Our results demonstrate that OKA can mimic the effects of DPH by selectively enhancing the cytotoxicity of VBL but not doxorubicin or taxol. Furthermore, unlike VBL alone, anti-mitotic effects from damage to the mitotic spindle as well as cell death by apoptosis (Kerr et al., 1994; Smets, 1994 ) is pronounced following treatment with VBL plus DPH or OKA.
Materials and methods
The human promyelocytic leukaemia HL-60 cells obtained from the American Type Culture Collection, Rockville, MD, USA were cultured in RPMI-1640 (M.A. Bioproducts, Gaithersburg, MD, USA) supplemented with 2 mM Lglutamine and 10% fetal bovine serum (M.A. Bioproducts). Human non-small-cell lung carcinoma NSCLC-3 cells, established in culture (Wells et al., 1994 ) from a surgical specimen was maintained in RPMI-1640 supplemented with 2 mM Lglutamine and 20% fetal bovine serum (FBS) . Doubling time in culture of the HL-60 and NSCLC-3 cells was 40 h and 50h respectively. The choice of these model systems was based on the need to establish the modulating efficacy of DPH with VBL in human tumours as well as tumours not restricted to the haematopoietic system. The effect of DPH or OKA on the mitotic block and cytotoxicity induced by VBL was determined in HL-60 or NSCLC-3 cells treated for 48 h with DPH or OKA alone and in combination with VBL. Control and treated cells were subsequently analysed for: (a) cytotoxicity; (b) mitotic arrest and spindle damage by immunofluorescence using an atubulin antibody; and (c) apoptosis based on immunofluorescent detection of 3'-OH ends of DNA labelled with fluorescein-12-dUTP or DNA fragmentation by agarose gel electrophoresis.
In vitro cytotoxicity Cytotoxicity was determined either by trypan blue dye exclusion using a haemacytometer or in a soft-agar colony assay. The soft-agar colony assay was carried out by plating control or treated cells in RPMI-1640 supplemented with 2 mM L-glutamine, 20% FBS and 0.3% agar. Following incubation for 10 days in a humidified 5% carbon dioxide plus 95% air atmosphere, the colonies were counted using an automated counter (Ganapathi et al., 1993 were grouped to quantify abnormalities. Morphology of the spindles were also examined for collapse of the spindle and for heavily condensed and/or fragmented mitotic apparatus (Vandre and Wills, 1992) .
Detection of apoptotic cells Microscopic evaluation was carried out as described by Gavrieli et al. (1992) . Briefly, cytospin preparations were labelled using terminal transferase and fluorescein-12-dUTP (Boehringer Mannheim, Indianapolis, Ins, USA). Slides were examined in a fluorescence microscope as described earlier and apoptotic cells scored by counting a minimum of 200 cells per field in three separate fields.
Agarose electrophoresis for internucleosomal fragmentation was carried out as described by Grant et al. (1992) . Briefly, control and treated cells (20 x 106) in lysis buffer (5 mM Tris base, 20 mM EDTA, 0.5% Triton X-100, pH 8.0 + 100 mg ml-' proteinase K) were incubated at 56°C for 18 h and centrifuged at 30000 g for 45 min at 4°C to separate the low molecular weight fragments. The supernatant was subsequently incubated at 37°C for 4 h in the presence of 100 fig ml-' RNAase A. The electrophoresis was performed in 2% LMP agarose (BRL, Life Technologies, Gaithersburg, MD, USA) in TAE buffer (40 mM Tris-acetate, 1 mM EDTA, pH 8.3) containing ethidium bromide. Samples were loaded onto the gel after mixing with 15% Ficoll and a 100 bp DNA ladder was used as a marker. After overlay of the gel with TAE buffer electrophoresis was carried out for 3 h at 65 V and the gel visualised under ultraviolet light.
Results and discussion
The data in Figure 1 demonstrate that DPH in a dosedependent fashion enhances the cytotoxic effect of VBL in HL-60 or NSCLC-3 cells. While these observations extend our earlier findings with VCR, an important distinction was the requirement of simultaneous exposure to VBL plus DPH for at least one cell generation cycle for maximal potentiation of cytotoxicity. In order to determine a mechanistic basis governing the cellular effects of DPH in enhancing VBL cytotoxicity, HL-60 or NSCLC-3 cells were treated with VBL and/or DPH for 2 days followed by recovery for an additional 4 days in drug-free medium. The experimental design with HL-60 cells also involved high concentrations of VBL alone, to rule out that effects of VBL + DPH were merely related to altered drug levels and damage. The results in Figure 2a indicate that while differences between VBL or VBL + DPH were minimal during drug exposure, the recovery of proliferation in drug-free medium of VBL-treated cells was similar to the untreated control, in contrast to a persistent abrogation of proliferation in cells treated with VBL + DPH. The mitotic block induced (Figure 2b) between VBL or VBL + DPH was similar at the end of treatment and a rapid reversal to control values was apparent within 2 days in drug-free medium. In contrast, while apoptosis in VBLtreated cells during recovery in drug-free medium was similar to the control, the apoptotic response was maximal and persistent with VBL + DPH (Figure 2c ). To characterise whether these findings with VBL + DPH were unique to leukaemic cells, the lung cancer NSCLC-3 model system was also evaluated. The data in Figure 3a demonstrate that only cells treated with VBL + DPH exhibit compromised recovery of proliferation in drug-free medium. The mechanistic basis for the compromised recovery of proliferation in drug-free medium in cells treated with VBL + DPH is possibly due to abnormal mitotic spindle (multipolar) morphology ( Figure  3b ) and the dominant persistence of an apoptotic response (Figure 3c ). Overall, either in leukaemic HL-60 or lung cancer NSCLC-3 cells, the combination of VBL + DPH results in persistent growth arrest and apoptosis even in drug-free medium. Notably, within the range of VBL concentrations that can be achieved clinically with manageable toxicity (Rowinsky and Donehower, 1992) , our data suggest that VBL, unlike VBL + DPH, is cytostatic. Data on double labelling (a-tubulin/fluorescein-12-dUTP) in Table I Based on the suggested role for protein phosphatases in egulating mitotic events and cytoskeletal integrity Yamashita et al., 1990; Eriksson et al., 1992; Fernande et rl., 1992; Vandre and Wils, 1992; Gurland and Gundersen, 993) , in the next series of experients using the HL-60 model ystem we investigated the effect of the protein phosphatase a
inhibitor OKA on the mitotic index, induction of apoptosis and cytotoxicity with VBL, using the human promyelocytic leukaemia HL-60 cells. The modulating effect of OKA on cytotoxicity was determined at the IC50 of doxorubicin (DOX), VBL or taxol (TXL) alone, which was obtained from dose-response curves. The data in Figure 4 indicate that a concentration of 10 nM OKA, which by itself is marginally cytotoxic (<5% cell kill), enhances the cytotoxic effects of VBL > 3-fold. In contrast, enhancement of cell kill observed with the combination of OKA and the mechanistically Figure 4 using a series of t-tests adjusted for multiple testing indicated that the combination of VBL + OKA was significantly (P = 0.001) more effective than either VBL or OKA alone. The results for TXL and DOX were less definitive. While the pleiotropic cellular effects of OKA are recognised, it is important to note that under the experimental conditions, OKA selectively enhances the cytotoxicity of VBL vs TXL or DOX, and the negative control compound, 1-nor-okadaone, which resembles OKA in physical properties and chemical structure, does not enhance VBL cytotoxicity at concentrations as high as 100 nM. The ability of OKA to mimic DPH in the potentiation of anti-mitotic effects and induction of apoptosis induced by VBL is also supported by data in Figure 5 , which demonstrate that unlike VBL alone, the combination of VBL and OKA results in an increase of > 3-fold and > 2-fold of mitotic and apoptotic cells respectively. Since cells demonstrating apoptosis based on labelling with fluorescein-12-dUTP exhibited nuclear chromatin condensation and segregation, we also determined internucleosomal DNA fragmentation by agarose gel electrophoresis. As shown in Figure 6 the formation of a 200 bp DNA ladder characteristic of apoptotic cell death is markedly enhanced only with the combination of VBL + OKA (Figure 6a ) and VBL + DPH (Figure 6b ).
Tumour cell insensitivity to VBL is generally accepted to be due to drug efflux by P-gp (Endicott and Ling, 1990; Gottesman and Pastan, 1993) . We now demonstrate that the (Rall and Schleifer, 1990) or the protein phosphatase inhibitor OKA (Vandre and Wills, 1992) can selectively enhance VBL cytotoxicity in human leukaemic or NSCLC-3 cells due to sustained growth arrest, damage to the mitotic spindle and induction of apoptosis. Both DPH or OKA can inhibit cell-cycle traverse in the mitotic cycle, leading to arrest in metaphase (MacKinney, 1980; Vandre and Wills, 1992) . Metaphase arrest induced by DPH is suggested to involve effects on polymerisation of tubulin (MacKinney, 1978) , while with OKA, inhibition of phosphatases involved in the mitotic cycle has been reported (Yamashita et al., 1990; Vandre and Wills, 1992) . Since concentrations of DPH that are capable of inducing measureable effects on polymerisation-depolymerisation kinetics of purified tubulin or metaphase arrest of treated cells are in excess of 300 gtm (MacKinney, 1978) , it is possible that alternate mechanisms are involved in the modulation of VBL cytotoxicity. Growth arrest by OKA in metaphase (Yamashita et al., 1990; Vandre and Wills, 1992) is suggested to involve inhibition of dephosphorylation events regulating metaphase to anaphase transit (Yamashita et al., 1990; Fernande et al., 1992; Vandre and Wills, 1992) . Other effects of OKA during the mitotic cycle include activation and inactivation of p349 kinase and possible suppression of the cyclin proteolysis pathway (Yamashita et al., 1990) . There is no direct evidence demonstrating effects of OKA on tubulin, but inhibitors of protein phosphatases such as OKA and calyculin A affect regulation of microtubule stability by the selective breakdown of stable microtubules in fibroblasts or epithelial-like cells (Gurland and Gunderson, 1993) .
The induction of apoptosis in OKA (> 30 nM)-treated cells has been reported (Zheng et al., 1994 
